Key terms
About GANX
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GANX news
Yesterday
12:15pm ET
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
Yesterday
6:30am ET
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
Apr 24
9:29am ET
Gain Therapeutics announces results from SAD part of Phase 1 GT-02287 trial
Apr 23
7:45am ET
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
Apr 08
4:32pm ET
Gain Therapeutics Welcomes New CFO Gene Mack
Apr 08
9:28am ET
Gain Therapeutics appoints Gene Mack as CFO
Apr 01
9:26am ET
Gain Therapeutics appoints Jonas Hannestad as CMO
Apr 01
6:18am ET
Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial Outlook
Mar 27
1:25pm ET
Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287
Mar 05
8:09am ET
Gain Therapeutics presents data at AD/PD 2024 conference
Feb 22
10:32am ET
Gain Therapeutics to host research and development day
Feb 07
6:16am ET
Buy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson’s Candidate GT-02287
Feb 06
8:12am ET
Gain Therapeutics announces preclinical data on GT-02287
Feb 01
3:35pm ET
Buy Rating Affirmed: Gain Therapeutics’ Promising GT-02287 Advances Towards Key Clinical Milestones in Parkinson’s Disease Treatment
Feb 01
6:50am ET
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Humana (HUM) and Boston Scientific (BSX)
Jan 31
8:05am ET
Gain Therapeutics issues letter to shareholders
No recent press releases are available for GANX
GANX Financials
Key terms
Ad Feedback
GANX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GANX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
